Nutrition articles

Top 5 most read type 1 diabetes articles in 2021

The most popular type 1 diabetes articles published in 2021 included new screening research and an updated coverage policy.

2021’s most read articles on type 1 diabetes (T1D) covered a wide range of topics, from islet transplantation to eligibility for CMS coverage. Other popular articles included research on optimal ages for T1D screening, effects of maternal diet, and approval of an interchangeable biosimilar.

5. An overview of islet transplantation

In this video, posted June 2021, Camillo Ricordi, MD, FNAI, Professor and Director of the Diabetes Research Institute and Cell Transplant Center at the University of Miami, Florida, describes how islet transplantation is performed and why it can benefit individuals with T1D. Essentially, the procedure allows the liver to perform its normal functions and that of a pancreas.

Watch the full video.

4. Optimal age for T1D screening

Data published in Diabetic treatments in May 2021 showed that the risk of developing islet autoimmunity decreases exponentially with age and indicated that the influence of the main genetic factors on this risk is limited to the first years of life. Islet autoimmunity precedes clinical T1D, and although the researchers did not specify a single time point, the highest sensitivity was achieved when screening between ages 3 and 5, while screening genetically at risk children at 2 time points increased sensitivity.

Read the article completely.

3. Maternal diet not linked to T1D risk

In May, researchers writing in Diabetology concluded that maternal food consumption in late pregnancy is not associated with the risk of islet autoimmunity or type 1 diabetes in the offspring. To assess this potential relationship, researchers compiled data from the Multicenter Observational Study of Environmental Determinants of Diabetes in Young People (TEDDY). The results were also robust to sensitivity analyses.

Read the article completely.

2. CMS aims to expand CGM coverage

New changes announced by CMS in June permanently eliminated the requirement of 4 or more tests per day for devices to qualify as continuous glucose monitoring (CGM) devices. This decision also expanded coverage for those using inhaled insulins by allowing multiple daily “administrations” of any insulin. Previously, this advice was limited to “injections” of insulin. The revisions came into effect in July 2021.

Read the article completely.

1. Approval of the first interchangeable biosimilar in the United States

The most read T1D story published in 2021 was the FDA’s approval of the first interchangeable biosimilar, insulin glargine, which allowed pharmacists to switch patients to the cheapest version of insulin without clinician’s approval. In the past, the insulin market has been the subject of congressional hearings and reports documenting the high cost of treating diabetes. The move comes after the insulins were added to biologics approved under the Biologics Price Competition and Innovation Act approval pathway in 2020.

Read the article completely.